Abstract:

BACKGROUND: Current treatments of hyperplastic scar are poor and limited, so it is necessary to seek a new effective drug to treat the hyperplastic scar.
OBJECTIVE: To investigate the effect of recombinant human endostatin injection on hyperplastic scars of New Zealand big-eared rabbit ears.
METHODS: 16 New Zealand big-eared rabbit were used to establish hyperplastic scar animal models and then the rabbits were randomly divided into an experimental group and a control group with 8 rabbits in each group. After epithelialization of rabbit ear wound, rabbits in the experimental group were injected with recombinant human endostatin, and those in the control group were injected with physiological saline. After 30 days, changes in hyperplastic scar were observed and hematoxylin-eosin staining was performed to investigate the expression of vascular endothelial growth factor in the scar tissue by immunohistochemisty.
RESULTS AND CONCLUSION: At 30 days after intervention, the scar tissue color became weaker, texture was softer, and scar thickness was thinner in the experimental group than in the control group. Hematoxylin-eosin staining showed that compared with the control group, dermis was thinner, fibroblasts in unit area were fewer, exhibiting a parallel arrangement, and capillary caliber was smaller in the experimental group. The hyperplastic scar index was significantly lower in the experimental group than in the control group (P < 0.01). Vascular endothelial growth factor positive expression in the experimental group was significantly lower than that in the control group (P < 0.01). These findings suggest that recombinant human endostatin injection maybe a better choice for treating hyperplastic scar by decreasing vascular endothelial growth factor protein expression.